Early Short Course Corticosteroids in COVID-19

NCT04374071 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2020-05-05

No results posted yet for this study

Summary

The investigators intend to study the role of early use of methylprednisolone in the hospitalized patients with a diagnosis of COVID-19 pneumonia.

Conditions

Interventions

DRUG

Methylprednisolone

IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Mayur Ramesh · Henry Ford Health System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2020-03-27
Completion
2020-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04374071 on ClinicalTrials.gov